How changes in lung tissue structure drive fibrotic lung disease

Stromal tissue-macrophage interactions in pulmonary fibrosis

In this project, academic partners from the University of Groningen will collaborate with partners from Boehringer Ingelheim to understand the cues for the derailed activity of specific immune cells, so-called macrophages, in the lung disease pulmonary fibrosis. These cells contribute to the disease process in pulmonary fibrosis, which results in increased stiffness of lung tissues leading to difficulties with breathing. It is hypothesised that the tissue micro-environment of the macrophages, which includes structural protein fibers and the cells that produce these, stromal (stem) cells, are responsible for the abnormal repair of lung tissue in fibrosis. These alterations in the tissue then act in a self-amplifying manner, driving macrophages to promote the fibrotic response.

Lung fibrosis is a rare, debilitating disease that affects around 3000 people in the Netherlands. It has a high impact on quality of life of patients and a mortality rate worse than most cancers. Lung fibrosis cannot be cured and there are very few drugs to treat this disease, creating an urgent need for novel therapeutic strategies.

In order to find new therapeutic strategies, it is needed to obtain more insight into the disease mechanisms. In this project, they will investigate whether the abnormal activity of stromal (stem) cells and/or the composition of the lung tissue and the abundance of structural proteins in fibrotic lungs alter the behavior of macrophages. They will use cells and tissue from the lungs of healthy controls and lung fibrosis patients and combine these in novel 3-dimensional culture models to study the effects on macrophages and determine which components are crucial for inducing the pathological changes.

Through comparing responses in diseased and non-diseased microenvironments it will become clear which factors contribute to the altered behavior of macrophages. With this knowledge it is expected to identify novel therapeutic targets for pulmonary fibrosis, which will be validated in their model system.

Summary
In pulmonary fibrosis, changes in the extracellular matrix (ECM) proteins produced by fibroblasts and mesenchymal stem cells (MSCs) create an altered tissue microenvironment, including increased stiffness. We hypothesise that the pathologically altered microenvironment interacts with macrophages, contributing to the pathology of the disease by regulating MSC repair and immunomodulatory responses.
Technology Readiness Level (TRL)
1 - 3
Time period
49 months
Partners
Logo
Logo
Logo